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Abstract: Cryopyrin-associated periodic syndromes (CAPS) are a subgroup of the hereditary 
periodic fever syndromes, which are rare autoinflammatory and inherited disorders, characterized 
by recurrent inflammation and varying degrees of severity. CAPS are thought to be driven by 
excessive production of interleukin-1β (IL-1β), through over-activation of the inflammasome 
by gain of function mutations in the gene encoding cryopyrin (NLRP3). This conclusion is sup-
ported by the remarkable efficacy of IL-1β blockade in these conditions. Rilonacept (ArcalystTM; 
Regeneron) is the first uS Food and Drug Administration-approved treatment for familial cold 
autoinflammatory syndrome and Muckle–Wells syndrome and the first in a new line of drugs 
designed for longer-acting IL-1 blockade. Rilonacept has been associated with a decrease in 
disease activity, high-sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) in 
the treatment of CAPS. The clinical safety and efficacy of rilonacept in CAPS and non-CAPS 
populations will be summarized in this review. Rilonacept is also beneficial for patients who 
tolerate injections poorly, due to an extended half-life over the unapproved CAPS treatment, 
anakinra, requiring weekly rather than daily self-administration. Other autoinflammatory dis-
orders may also benefit from rilonacept treatment, with clinical trials in progress for systemic 
onset juvenile idiopathic arthritis, gout and familial mediterranean fever.
Keywords: cryopyrin-associated periodic syndromes, rilonacept, interleukin-1, IL-1 TRAP, 
inflammasome, autoinflammatory
Introduction
Cryopyrin-associated periodic syndromes (CAPS) are a group of rare autoinflammatory 
and inherited disorders with many symptoms in common, including recurrent attacks 
of systemic inflammation and fever, often the subject of misdiagnosis. They include 
familial cold autoinflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS), 
and neonatal onset multisystem inflammatory disorder (NOMID) (also known as 
chronic infantile neurologic cutaneous and articular syndrome [CINCA]).1–4 CAPS are 
characterized by recurrent inflammation widely thought to be driven by an excessive 
production of interleukin-1 (IL-1) family member IL-1β, supported by patient response 
to IL-1β blocking therapies.5–8 IL-1β binds to the IL-1 receptor I (IL-1RI) and signal 
transduction is facilitated by the recruitment of IL-1R-accessory protein (IL-1RI-AcP) 
(Figure 1). IL-1Ra is a specific receptor antagonist that is an endogenous control of 
IL-1 signalling. IL-1β has key roles in fever, hematopoiesis, appetite control, and bone 
metabolism and is known to be a key mediator of immune response,9 able to regulate the 
production of several well documented proinflammatory mediators including cytokines, 
chemokines and matrix metalloproteinases.10–12 IL-1β has diverse signalling potential 
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and as such is tightly controlled by several mechanisms. FCAS 
are MWS thought to arise from mis-sense mutations of the 
NLRP3 (CIAS1) gene encoding NLRP3 (cryopyrin), which 
can also be found in severe cases of CINCA.13–16 NLRP3 
is a component of a multiprotein complex known as the 
inflammasome, which is an important regulator of immune 
response.17,18 The inflammasome is known to recognize and 
respond to a range of stimuli including pathogen-associated 
molecular patterns (PAMPs) like lipopolysaccharide from 
gram-negative bacteria and also endogenous stimuli termed 
damage-associated molecular patterns (DAMPs) such as uric 
acid.19 NLRP3 inflammasome assembly leads to the activation 
of caspase-1, which in turn facilitates the maturation of IL-1β, 
IL-18 and IL-33 (Figure 1).14,20 Traditional anti-inflammatory 
treatments for CAPS include the use of corticosteroids, 
disease-modifying antirheumatic drugs (DMARDS) and 
anti-tumor necrosis factor (anti-TNF) therapy. Anakinra 
was the first biologic designed for the selective blockade of 
IL-1 that was shown to have clinical efficacy in patients with 
MWS, when administered by daily subcutaneous injection.8,21 
Response to IL-1 therapy supported the hypothesis of IL-1β 
dysregulation being a key mediator in CAPS. Anakinra is a 
human recombinant IL-1 receptor agonist (rhIL-1Ra), similar 
to endogenous IL-1Ra. Due to the initial success of anakinra 
and subsequent studies further supporting the clinical efficacy 
of IL-1 treatment for FCAS and MWS,21–23 progress has been 
made with the development of novel selective IL-1 biologics. 
One such biologic is canakinumab (ACZ885; Novartis 
Pharma), a fully humanized monoclonal antibody targeted 
against IL-1β with FDA approval for the treatment of FCAS 
and MWS. The drug has been able to show good tolerability 
and has the advantage of an extended half-life over anakinra, 
conferred by monoclonal therapy.24 Rilonacept (ArcalystTM; 
Regeneron) pioneered this new generation of IL-1 targeted 
therapies in CAPS. The drug was the first FDA approved 
biologic for use in the treatment of FCAS and MWS after 
demonstrating remarkable clinical safety and efficacy.
Clinical manifestations of CAPS
Patients with FCAS and MWS have a significant symp-
tom overlap and commonly include fatigue, fever, rash, 
inflammation of the skin, eyes, bones, joints, and meninges. 
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Figure  The NLRP3 inflammasome is generally assembled upon activation by a range of pathogen-associated molecular patterns through pattern recognition receptors (PRRs) 
such as TLRs (eg, LPS activation of TLR4), or by interaction with components of internalized damage associated molecular pattern molecules (eg, uric acid crystals) leading to 
IL-1 cytokine maturation. Mutations to the NACHT domain of the NLRP3 subunit can result in spontaneous activation of the inflammasome and may lead to over-production 
and secretion of IL-1β, which is thought to be a causative factor in the clinical manifestations of CAPS.
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Symptoms can have onset in infancy, with patients often 
experiencing episodes on a daily basis. There is a strong 
link to low temperature-induced episodes in FCAS 
patients, while the factors initiating symptoms in MWS 
are not as apparent they are thought to include cold, stress 
and exercise. Those with NOMID/CINCA are the most 
severely affected, owing to inflammation of the central 
nervous system. Symptoms include seizures, abnormal 
bone growth, ocular, visual and cognitive impairment as 
well as a range of musculoskeletal defects. It is estimated 
that the incidence of CAPS is one in a million worldwide, 
though symptoms have historically been misdiagnosed due 
to the physician unfamiliarity with these rare conditions. 
Patients suffer from recurrent and debilitating flares which 
have a dramatic impact on both personal and professional 
life.25 Effective treatments have only just started to emerge 
and utilize biologics designed for IL-1 blockade. The bio-
logic rilonacept offers significant clinical benefit for the 
treatment of FCAS and MWS, which will herein be the 
focus of this review.
Rilonacept – mode of action
Rilonacept, a product of TRAP (Target-Related Affinity 
Profiling) technology developed by Regeneron pharmaceu-
ticals,26 is a dimeric fusion protein composed of the ligand 
binding domains of the extracellular portions of the human 
IL-1RI and the IL-1R-AcP linked to the human IgG1 Fc 
domain (Figure 2). Rilonacept acts similar to the endogenous 
IL-1RA soluble decoy receptor by binding IL-1β but with 
100 times greater affinity than native receptors. The drug 
is also able to bind IL-1RA and IL-1α though with lower 
affinity. Blockade of both IL-1α and IL-1β may be advanta-
geous by further limiting IL-1 signalling potential. Rilonacept 
acts to sequester IL-1 and thereby prevents interaction with 
endogenous cell-surface receptors, resulting in a reduction 
of IL-1-mediated signal transduction events, which are 
known to induce inflammation.26
Pharmacology
In adult patients aged 18 years or older, rilonacept should 
be administered with an initial loading dose of 320 mg, 
delivered by subcutaneous injection (SI) to two separate 
sites, followed by weekly injections of 160 mg. No dosage 
adjustments are required in adults. In pediatric patients from 
12 to 17 years of age, an initial loading dose of rilonacept 
should be given at 4.4 mg/kg up to a maximum of 320 mg, 
followed by weekly injections of 2.2 mg/kg up to a maxi-
mum of 160 mg at one or two different sites. Rilonacept 
has a high therapeutic index and can be administered to a 
broad population. The dosage size does not affect the drugs 
terminal half-life, with only a relatively small effect on 
clearance within a broad dose range (50 µg/kg to 2000 mg). 
The terminal half-life in the pediatric patients (6.3 days) is 
slightly shorter than in the adult population (7.0 days); due 
to their similarity no adjustment in the dosing schedule is 
required. Individual studies of rilonacept found both the 
maximum concentration (C
max
) and area under the curve 
(AuC) increased proportionally with the dose administered, 
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Figure  A diagram to illustrate the structural differences of the endogenous IL-1 receptor complex and the designer protein rilonacept. A) Rilonacept – a dimeric protein 
comprising the IL-1RI chain and IL-1R-ACP chain, linked by fusion to Fc domains which confer an extended half-life. B) endogenous membrane bound IL-1 receptor complex 
of IL1-RI and IL-1R-AcP. Both receptor chains are required for IL-1 binding to initiate signal transduction. Rilonacept is able to bind IL-1β with greater affinity.
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evaluated up to a maximum of 320 mg. The weight-adjusted 
C
max
 was approximately 17 µg/mL in healthy patients with 
mean steady-state trough values, following weekly SI of 
100 mg, increasing proportionally with the dose up to a 
maximum of 11.8 µg/mL. In CAPS patients, the mean 
steady-state trough levels of rilonacept ranged from 20 to 
27 µg/mL, after weekly SI of 160 mg for up to 48 weeks. 
Steady-state appeared to be reached by 6 weeks of treatment. 
The terminal phase elimination half-life was approximately 
7 days, and was dose independent, with an absorption phase 
half-life of approximately 1.8 days, after SI. This figure was 
derived from the population pharmacokinetic estimate of the 
absorption rate constant (half-life = ln(2)/Ka).27
Similar values were obtained for rilonacept in patients 
with end-stage renal disease (ESRD) on hemodialysis and 
CAPS patients. The terminal half-life for ESRD patients was 
7.36 days compared to 8.86 days in CAPS. Clearance was also 
similar between the two populations 0.829 L/day (ESRD) and 
0.808 (CAPS). Based on these results a dose adjustment was 
not required in ESRD patients as there was no evidence that 
renal failure slowed elimination of rilonacept. The detection 
of low titer anti-rilonacept antibodies in a number of patients 
during the course of treatment had no significant affect on 
pharmacokinetic parameters.27
Though no study has been reported so far, limited clinical 
data suggest that rilonacept steady state is not affected by 
the patient’s sex, age (26 to 78 years) or body weight (50 to 
120 kg). Since only Caucasian patients were enrolled into 
this study, the affect of ethnicity could not be evaluated.28
Clinical studies in CAPS
Rilonacept was granted uS Food and Drug Administra-
tion (FDA) approval and given ‘orphan drug’ status upon 
two sequential phase III clinical studies (supported by 
Regeneron), based on the favorable findings in an open-label 
pilot study to investigate the safety and efficacy of rilona-
cept in 5 patients with FCAS.22 In the open-label pilot all 
patients following a baseline evaluation, received rilonacept 
at an initial loading dose of 300 mg by SI given over 3 days. 
Efficacy and safety were evaluated at 6 and 10 days post 
treatment, patients remained off treatment unless a disease 
flare occurred. In this instance patients then received 300 mg 
of rilonacept and were maintained on 100 mg weekly doses. 
All patients entered the extended phase of the trial and were 
followed up for a period of 24 months. Four of the 5 patients 
who failed to go into remission, as determined by inflamma-
tory markers (high-sensitivity CRP [hsCRP] 0.5 mg/dL 
and/or serum amyloid A [SAA] 10 mg/L and a daily diary 
score of 0.5, not achieved), were eligible for an escalated 
dosage in the extended phase with rilonacept administered 
at 160 mg per week and 320 mg per week if after 4 weeks 
they still failed remission criteria. All patients responded 
to treatment within several hours, showing signs of reduc-
tion in rash, fever and arthralgia. Significant reduction in 
erythrocyte sedimentation rate (ESR), hsCRP and SAA 
were achieved at 100 mg per week and further improve-
ment achieved at higher dose administration (statistically 
significant for ESR [P  0.05]) with no serious adverse 
affects. Rilonacept demonstrated a sustained suppression 
of IL-1β-induced inflammation and patients demonstrated 
good tolerability.
Rilonacept was further evaluated for safety and efficacy 
in two sequential phase III clinical studies (supported 
by Regeneron) in patients with CAPS.29 Of the 47 adult 
patients enrolled 44 completed both studies. Each CAPS 
patient was found to have an NLRP3 mutation, and exhibited 
signs and symptoms of FCAS or MWS (44 with FCAS and 
3 with MWS).
Study 1 was randomized, double-blinded and placebo 
controlled. Patients received an initial 320 mg dose of 
rilonacept followed by a weekly dose of 160 mg or placebo 
for 6 weeks by SI. In study 2, all subjects were given 160 mg 
rilonacept weekly for 9 weeks in the single-blind phase, 
followed by a 9 week randomized, double-blind withdrawal 
period in which patients were randomly assigned rilonacept 
at a dose of 160 mg per week or administered placebo. 
Efficacy was evaluated at 3-week intervals in the clinic and 
by using Daily Health Assessment Form (DHAF) to assess 
disease-related symptom severity to encompass feelings of 
fever/chills, joint pain, eye redness/pain and fatigue.
In study 1 of 44 patients, 24 received rilonacept and 
demonstrated a significant reduction in mean key symptom 
score in the first 24 hours of treatment compared with the 
23 patients randomized to the placebo. Rilonacept was 
significantly better than the placebo with reduced multi-
symptom and single-symptom flares (P  0.0001 for 
each comparison) with a low mean key symptom score 
(P  0.0001). Improvement was also seen in patient and 
physician disease activity scores (P  0.0001 for each 
comparison) as well as decreased hsCRP (P  0.0001) and 
SAA (P = 0.006).
In study 2 – part A, patients randomized to rilonacept 
continued with treatment and maintained the benefits from 
the first part of the study. Patients previously on the placebo 
were switched to rilonacept and showed rapidly improve-
ment in key symptoms, hsCRP and SAA. Part B, showed 
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rilonacept to be significantly superior to the placebo in 
maintaining reduced multisymptom flares (P = 0.003), single 
symptom flares (P  0.001) and a low mean key symptom 
score (P = 0.0002).
Safety and tolerability
Treatment with rilonacept was well tolerated in the initial 
open-label pilot study of 5 FCAS patients, who all main-
tained 100% compliance with the treatment.22 Adverse 
events were classified as mild or moderate, with no patient 
requiring discontinuation of rilonacept. The most common 
adverse event was respiratory tract infection that resolved 
over the course of the study. One patient with pre-existing 
basal cell carcinoma had 2 new lesions removed during 
the study and 1 patient with pre-existing oral ulcers indi-
cated an increased frequency and prolonged healing of 
these ulcers while receiving rilonacept. Two patients had 
significant weight gain of 11.3 kg and 13.0 kg, respectively. 
No injection site reactions occurred during the course of the 
study. No serious adverse events occurred in these 5 patients 
and higher dosage levels did not correlate with an increased 
in adverse events.
Rilonacept was also well tolerated by patients enrolled 
in the subsequent phase III clinical trials.28 In the phase III 
study 1, the most common adverse events were injection 
site reactions and upper respiratory tract infections. A total 
of 17 (74%) patients receiving rilonacept and 13 (54%) 
patients receiving the placebo had treatment related adverse 
events. The injection site reactions included erythema, 
swelling, pruritis, mass, bruising, inflammation, pain, 
edema, dermatitis, discomfort, urticaria, vesicles, warmth 
and hemorrhage. The next most commonly reported adverse 
event was upper respiratory infection. Most injection site 
reactions lasted for 1 to 2 days and none were assessed 
as severe. There were no serious adverse events reported 
during these studies. In study 1, infections reported by 
patients (treated in the winter months) administered with 
rilonacept compared to those on placebo were 48% and 17% 
respectively. In study 2 – part B, the randomized withdrawal 
phase (taking place in the summer months), patient reports 
of infection were similar between rilonacept (18%) and 
the placebo (22%). Rilonacept was evaluated in a range 
of patient populations, where infection incidence was also 
found to be similar with 34% of 360 patients treated with 
rilonacept and 27% of 179 patients treated with placebo.27 
The most frequent adverse events for patients treated with 
rilonacept in study 2 – Part B were injection site reaction, 
headache, arthralgia and diarrhea. In study 2 – part A, 
2 patients discontinued treatment; in 1 patient this was 
due to pre-existing elevations in transaminase levels, later 
determined to be caused by hepatitis C viral infection and 
the another was due to worsening joint pain in two fingers. 
In study 2 – part B, 1 patient reported a serious adverse 
event presenting in worsening sciatica. All serious adverse 
events were judged by the investigator to be unrelated to 
rilonacept treatment. Where rilonacept was used in unap-
proved indications; one patient on chronic glucocorticoid 
treatment, developed a mycobacterium intracellulare infec-
tion and another 71-year-old patient acquired Streptococcus 
pneumoniae meningitis that resulted in death.29
Further safety considerations
The open-label FCAS study22 found significant increases 
in red blood cell count and hemoglobin; neutrophils 
(-1.9 k/mm3) and platelets (67 k/mm3) may be decreased, 
however did not fall below reference range. CAPS patients 
6 weeks after rilonacept treatment, showed an increase 
from baseline in mean total cholesterol (19 mg/dL), high-
density lipoprotein cholesterol (2 mg/dL), low-density 
lipoprotein cholesterol (10 mg/dL) and triglycerides 
(57 mg/dL). Patients may be at increased risk of develop-
ing cardiovascular complications. CAPS patients in the 
open label extension who had received rilonacept for at 
least 6 weeks found 19 of 55 patients (35%) tested posi-
tive for anti-rilonacept antibodies, using high-sensitivity 
ELISA detection, on at least one occasion. Efficacy and 
safety appeared unaffected and their clinical significance 
is unclear. The upper limit for the dosage of rilonacept has 
not been established; intravenous infusion at doses up to 
2000 mg monthly has been tolerated in a non-CAPS popu-
lation for up to 6 months. One patient developed transient 
neutropenia (ANC  1 × 109/L), but did not develop an 
associated infection.28
Other considerations
Due to the immunosuppressive nature of rilonacept in 
sequestering IL-1α and IL-1β and concomitant signaling 
affects, there are a number of risk factors that have not been 
through rigorous study. No data concerning vaccination while 
on rilonacept are available and it is highly recommended for 
all vaccinations to be taken before treatment commences. 
No studies have evaluated safety in pregnant women and it 
is advised rilonacept should not be taken unless there are sig-
nificant benefits out weighting the potential risk involved to 
the fetus. Cytochrome-C p450 (CYP450) levels may increase 
during the course of rilonacept treatment stemming from the 
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finding that during chronic inflammation, CYP450 levels 
can be suppressed by high cytokine levels. These patients 
may be receiving modifying drugs such as warfarin, which 
has a narrow therapeutic index and these patients may be at 
increased risk of adverse events. Patients who have or develop 
infections, chronic infections, who are immunocompromised, 
those on anti-TNF- or other IL-1-blocking therapies or 
become hypersensitive should not take rilonacept for risk of 
developing severe adverse events.28
Rilonacept in non-CAPS 
populations
Rilonacept has potential for the treatment of a number of 
other autoinflammatory disorders including familial Mediter-
ranean fever (FMF),30 TNF-associated periodic syndromes 
(TRAPS),31 diabetes,32 atherosclerosis,33 chronic gout,34 
and systemic onset juvenile idiopathic arthritis (SoJIA).35 
Regeneron, among other pharmaceutical companies, are 
currently conducting clinical studies in disorders where IL-1 
may play an important role (see Table 1). The rilonacept trials 
where data are already available are described.
Gout
Patients with gout are largely treated with nonsteroidal 
anti-inflammatory drugs (NSAIDs) or colchicine, although 
corticosteroids may also be administered where these treat-
ments cannot be used. urate lowering therapies, such as 
allopurinol, are also used in combination with prophylactic 
treatment to reduce flare incidence and severity.36 While tradi-
tional treatments remain suboptimal, IL-1 targeted treatment 
has demonstrated potential. A nonrandomized, single-blind 
controlled pilot study was carried out to evaluate the benefit 
of rilonacept in chronic gouty arthritis.34 All 10 patients 
enrolled in the study had a history of chronic gouty arthritis 
with inflamed joints for 4 or more weeks prior to enrolment. 
Placebo was given for 2 weeks before an initial loading dose 
of 320 mg of rilonacept was administered by subcutaneous 
injection. This was subsequently followed by 5-weekly 
injections of 160 mg of rilonacept, before patients entered 
a 6-week withdrawal phase. Clinical responses were evalu-
ated by 10 point/21 increment visual analogue scale (VAS), 
patient and physician global assessment, joint count and 
hsCRP levels. Sixty percent (6 of 10) of patients reported at 
least a 50% improvement in self-reported VAS pain scores 
(P = 0.001) while 50% (5 of 10) reported at least 75% 
improvement (P  0.01). These improvements were not 
sustained in the withdrawal period. hsCRP levels fell from 
0.4 mg/dL (following placebo) to 0.02 mg/dL after rilona-
cept treatment (P = 0.004). Treatment was well tolerated, 
with the most common adverse event being injection site 
reaction. One 50-year-old patient withdrew from treatment 
due to severe injection site erythema and induration, both 
of these adverse events were judged by the investigator to 
be related to study treatment. Three patients were found to 
have anti-rilonacept antibodies (non-neutralizing), though as 
efficacy and safety were apparently unaffected their clinical 
significance is unclear. Regeneron supported a double-blind, 
placebo-controlled phase II clinical study of 83 gout patients 
that found an 81% reduction in the number of symptom 
flares per patient over 12 weeks of rilonacept treatment as 
compared to placebo (P = 0.0011).37
Systemic onset juvenile idiopathic 
arthritis (SoJIA)
SoJIA patients are often reliant on chronic corticosteroid 
treatment as the use of NSAIDs, methotrexate and anti-TNF 
treatment (eg, etanercept) can often prove ineffective. The 
risks associated with prolonged steroidal treatment include 
cataracts, growth retardation and vertebrae compression fac-
tures.38 Cytokine blockade in SoJIA has shown potential for 
disease treatment by clinical and in vitro studies.39,40 An initial 
4-week double-blind, placebo controlled study evaluated 
Table  A summary of new clinical trials evaluating rilonacept in other IL-1 related disorders as well as CAPS46
Study condition Responsible party Status Phase Est. completion
Familial Mediterranean fever Cleveland Clinic Recruiting II Mar 2011
Systemic onset juvenile  
idiopathic arthritis
National Institute of  Arthritis and  
Musculoskeletal and Skin Diseases
Recruiting II Dec 2011
Type 1 diabetes mellitus University of  Texas Southwestern  
Medical Center
Not yet  
recruiting
II Jun 2012
Acute gout flare Regeneron Pharmaceuticals Recruiting III Apr 2010
Intercritical gout Regeneron Pharmaceuticals Recruiting III Apr 2010
Gout Regeneron Pharmaceuticals Recruiting III Oct 2010
Gout Regeneron Pharmaceuticals Recruiting III Jan 2011
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21 active SoJIA patients (aged 5 to 20) administered with 
rilonacept by SI of 2.2 mg/kg/week (up to 160 mg) to 
4.4 mg/kg/week (up to 320 mg). After 4 weeks American 
College of Rheumatology criteria (ACR) Pedi 30/50/70 
were 76.2%/61.9%/33.3% respectively.41 The subsequent 
open-label extension study of 23 SoJIA patients, evaluated 
the safety and efficacy of rilonacept over 24 months with 
rilonacept given by SI at 2.2 mg/kg/week (up to 160 mg) to 
4.4 mg/kg/week (up to 320 mg). At 6 months during treatment 
ACR pedi 30/50/70 responses were seen in 87%/78%/61% of 
patients and 70%/70%/57% at 24 months. Sustained response 
was demonstrated in more than 50% of SoJIA patients over 
24 months in both clinical and laboratory assessments, with 
all patients able to stop steroidal treatment by 24 months. Six 
patients reported serious adverse events, including macro-
phage activation syndrome, pulmonary fibrosis, anemia and 
arthritis flare, which are unlikely to be as a result of rilonacept 
treatment. The most common adverse events were injection 
site reaction and upper respiratory infection.42 Differential 
cytokine blockade in SoJIA may be advantageous in tailoring 
treatment where current therapies have failed.
Managed treatment
Financial cost is often a key barrier associated with the use 
of biologics in disease treatment. Patients requiring life long 
treatment, can often be at significant financial disadvantage, 
an implication shown with anti-TNF biologics therapy.43 
A study of 36 patients prescribed anti-TNF biologics for the 
treatment of autoinflammatory disorders, found a correlation 
between the discontinuation of treatment and financial 
burden. Regular follow-ups over the course of 3 years found 
52% of patients (19 of 36) had discontinued treatment due 
to financial reasons while 8% of patients (3 of 36) continued 
but treatment was suboptimal with spaced out regimes.44 This 
study is representative of a global issue. Anakinra, an off label 
treatment with clinical efficacy in CAPS, is associated with 
an approximate monthly cost (based on average wholesale 
price) of uS$1515 and rilonacept, the FDA approved 
treatment for CAPS, has an approximate average monthly 
cost of uS$30,000.45 Regeneron have taken measures to help 
manage the cost of rilonacept therapy and have set up the 
Arcalyst Resource Centre (ARC) program to support insured 
patients with reimbursement, putting physicians familiar 
with diagnosing and treatment of CAPS in contact with 
patient’s insurance providers to determine coverage, obtain 
and assist with prior authorization requests and appeals. 
They can refer patients to foundations that may assist with 
high co-payments, while uninsured patients may be eligible 
for Regeneron’s assistance program that can offer the drug 
free of charge to qualifying patients or for non-qualifying 
patients, help with finding alternative coverage.45
Conclusions
IL-1β is intimately involved in the pathogenesis of CAPS. 
Many CAPS patients have mutations of the NALP3 gene with 
in vitro experiments demonstrating that mutation in this gene 
can lead to excessive IL-1β production through the activity of 
the NALP3 inflammasome. This was strongly supported by 
the remarkable success of the IL-1 targeted biologic anakinra. 
Since this initial success, new biologics designed for IL-1 
blockade have been designed, developed and granted FDA 
approval for the treatment of CAPS. Rilonacept pioneered this 
new generation of CAPS treatment offering significant clini-
cal advantages over the off-label treatment anakinra. The long 
term implications of treatment are unclear though the benefits 
may out way the risk for many. Due to the low incidence of 
CAPS the cost of approved treatment is presently higher than 
most other biologics, though a number of comprehensive 
programs are in place to help patient’s access treatment. 
The longer half-lives of the new biologics rilonacept and 
canakinumab, offer CAPS patients an alternative to past 
treatments and those who find daily injection intolerable or 
have trouble with compliance. The potential of selective IL-1 
blockade may see rilonacept augmenting existing treatments 
for other autoinflammatory disorders.
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